Abbott Laboratories [NYSE: ABT] gained 1.10% in the last trading session, reaching $ 127.82 per share at the time. The company’s report on November 9, 2021 that Abbott and the American Diabetes Association® are launching a one-of-a-kind community initiative in Columbus, Ohio, to advance access to diabetes care and technology.
– First program launched under the Health Equity Now ™ platform of the American Diabetes Association.
– The community program seeks to understand how to increase access to health technologies for underserved diabetes communities.
Abbott Laboratories has 1.77 billion shares outstanding, while the company has a total market value of $ 235.20 billion with the latest information. ABT’s stock price was found in a range of $ 126.05 to $ 128.11.
Compared to the average trading volume of 4.83 million shares, ABT reached a trading volume of 5,333,694 in the last day of trading, which is why market watchdogs consider the stock to be active. .
Here’s What Top Stock Market Gurus Are Saying About Abbott Laboratories [ABT]:
Based on careful, factual analysis by Wall Street experts, the current consensus on the target price for ABT shares is $ 138.41 per share. Analysis of target price and stock performance is usually carefully considered by market experts, and the current Wall Street consensus for ABT stock is a recommendation set at 1.90. This rating represents a strong buy recommendation, on a scale of 1 to 5, where 5 means a strong sell, 4 represents a sell, 3 is a hold, and 2 indicates a buy.
Atlantic Equities valued the shares of Abbott Laboratories, retaining its opinion on the stock as overweight, with its previous recommendation of October 27, 2021. While these analysts maintained the previous recommendation, Redburn raised its target price to Neutral. The new price target note was released on October 14, 2021, representing the official price target for the Abbott Laboratories share. Previously, the target price had risen further to $ 150, while analysts at Barclays maintained an overweight rating on ABT stock.
The Average True Range (ATR) for Abbott Laboratories is set at 2.21, with the price-to-sales ratio for ABT shares over the last 12 months being 5.56. The Price to Book ratio for the last quarter was 6.59, with the Price to Cash per share for the same quarter being set at 5.27. The free cash flow rate for ABT for the last twelve months was 37.52 with a Quick’s ratio for the last quarter of 1.40.
Analysis of trading performance for ABT stock
Abbott Laboratories [ABT] fell into the red zone at the end of last week, falling into a negative trend and falling to -0.68. With this latest performance, ABT shares have gained 8.95% over the past four weeks, on top of 8.83% over the past 6 months – not to mention a 15.35% rise in the past. last year of negotiation.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result above 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent neutral market dynamics. ABT’s current RSI for the last two-week period is set at 58.59, the RSI for the latest trading single is 58.54, and the three-week RSI is set at 57.69 for Abbott Laboratories. [ABT]. The current moving average for the last 50 trading days for this stock is 123.87, while it was recorded at 126.90 for the last week of trading and 120.45 for the last 200 days.
Abbott Laboratories [ABT]: A deeper dive into fundamental analysis
The operating margin of any stock indicates how profitable the investment would be and Abbott Laboratories [ABT] The stocks currently have an operating margin of +15.29 and a gross margin of +50.21. Abbott Laboratories’ net margin is currently recorded at +12.86.
The total ROI for ABT is now 10.24, given the latest swing, and the ROI for the company is 8.83. The return on equity for this stock was down to 13.93, with a return on assets of 6.34. With regard to the capital structure of this company, Abbott Laboratories [ABT] has a ratio of total debt to total equity set at 60.67. In addition, ABT’s total debt to total capital is recorded at 37.76, with total debt to total assets ending at 27.42. Long-term debt to equity of the company is recorded at 59.26, with long-term debt to total capital now standing at 36.89.
Reflecting on the efficiency of the workforce in the company, Abbott Laboratories [ABT] managed to generate an average of $ 40,817 per employee. The company’s receivables turnover is 5.85 with total asset turnover recorded at a value of 0.49. Equally interesting and compelling is Abbott Laboratories’ liquidity data, with a quick ratio of 1.40 and a current ratio set at 1.80.
Abbott Laboratories [ABT]: An analysis of earnings per share (EPS)
With the latest financial reports released by the company, Abbott Laboratories posted EPS of 0.98 / share, while average EPS was expected by analysts at 0.91 / share. When compared, the two values show that the company exceeded estimates by a surprise factor of 7.70%. The company’s progress can be seen through the prism of the EPS growth rate, while Wall Street analysts focus on forecasting the 5-year EPS growth rate for ABT. Regarding the mentioned value, analysts expect the 5-year EPS growth rate for Abbott Laboratories to reach 12.57%.
An Insider Ownership Analysis at Abbott Laboratories [ABT]
There are currently approximately $ 168,089 million, or 75.20% of ABT’s shares, in the hands of institutional investors. The three main institutional holders of ABT shares are: VANGUARD GROUP INC with ownership of 147,844,584, which represents approximately 0.871% of the market capitalization of the company and approximately 0.20% of the total institutional ownership; BLACKROCK INC., Holding 134,318,636 shares worth approximately $ 17.17 billion in ABT shares; and CAPITAL RESEARCH GLOBAL INVESTORS, which currently owns $ 10.97 billion in ABT shares and owns nearly 0.034% of the company’s market capitalization.
>> 7 top choices for the post-pandemic economy
Positions in shares of Abbott Laboratories held by institutional investors increased at the end of October and at the time of the reference period of October, when 1,130 institutional holders increased their position in Abbott Laboratories. [NYSE:ABT] by approximately 55,552,795 shares. In addition, 1,079 investors reduced their positions by approximately 57,706,683 shares, while 404 investors held positions with 1,201,786,252 shares. The mentioned changes put institutional holdings at 1,315,045,730 shares, according to the latest report filed with the SEC. ABT stock had 129 new institutional investments for a total of 5,799,612 shares, while 113 institutional investors sold positions of 3,823,142 shares during the same period.